Pharma BD Deal Intelligence
AstraZeneca paid $4B for 55% of Acerta Pharma to get acalabrutinib (Calquence), a next-gen BTK inhibitor designed to outperform ibrutinib on tolerability. Calquence reached $2.6B in annual sales, giving AZ a durable hematology franchise from a single molecule.
AstraZeneca acquired 55% of Acerta Pharma for $4B for BTK inhibitor.
AstraZeneca acquires 55% stake in privately-owned Acerta Pharma for $4 billion, with the agreement including options for AstraZeneca to buy the remaining…
Source summaries from our enrichment pipeline; follow links for originals.
All 4 sources with sentiment breakdown →
AstraZeneca acquired 55% of Acerta Pharma for $4B for BTK inhibitor.
MCL (~4,000 US diagnoses/year) is a BTKi-dominant niche being restructured by non-covalent BTKi and CAR-T in relapsed disease, with R/R settings increasingly crowded. Covalent BTK inhibitors: acalabrutinib (Calquence, AstraZeneca) received FDA accelerated approval for R/R MCL in 2017 and is now also tested in 1L ECHO; ibrutinib (Imbruvica, AbbVie/J&J) had its MCL indication voluntarily withdrawn April 2023 after SHINE/SELENE follow-up; zanubrutinib (Brukinsa, BeiGene) is approved for R/R MCL since 2019. Non-covalent BTKi: pirtobrutinib (Jaypirca, Eli Lilly) received FDA accelerated approval January 2023 for post-covalent-BTKi R/R MCL based on BRUIN — directly threatens Calquence post-progression economics. CD19 CAR-T: brexucabtagene autoleucel (Tecartus, Kite/Gilead) — $420M global in 2023 per Gilead IR, majority MCL — is the curative-intent 2L+ option post-BTKi. BCL-2 + anti-CD20: venetoclax (Venclexta, AbbVie) plus rituximab (Rituxan, Roche) or obinutuzumab (Gazyva) is used off-label/investigationally in BTKi-refractory disease. Bispecific T-cell engager: glofitamab (Columvi, Roche) received FDA accelerated approval for R/R MCL in 2025 after Phase 1/2 GO40515 — a new non-cellular competitor. Commercial lead takeaway: Calquence's 1L MCL share depends on ECHO readout vs chemo-immunotherapy and bendamustine-rituximab combinations; R/R share is eroding to Jaypirca and Tecartus.
CLL is a crowded multi-billion-dollar class dominated by covalent BTK inhibitors and BCL-2 inhibition, with non-covalent BTKi and CAR-T closing the resistance gap. Covalent BTK inhibitors: acalabrutinib (Calquence, AstraZeneca — $3.1B global 2023 per AZ IR, majority CLL/MCL), ibrutinib (Imbruvica, AbbVie/J&J — ~$5.3B combined 2023 but declining), and zanubrutinib (Brukinsa, BeiGene — $1.3B 2023, ~70%+ from CLL after ALPINE head-to-head superiority vs ibrutinib) compete directly. BCL-2 inhibitor: venetoclax (Venclexta/Venclyxto, AbbVie/Roche) generated $2.3B in 2023, primarily in fixed-duration VenO regimens (with obinutuzumab) in 1L CLL per CLL14. Anti-CD20 monoclonals: obinutuzumab (Gazyva, Roche), rituximab (Rituxan/Rituximab-biosimilars), and ofatumumab (Arzerra, Novartis) are used in combination backbones. Non-covalent BTKi: pirtobrutinib (Jaypirca, Eli Lilly) approved December 2023 for post-covalent-BTKi/BCL-2 relapsed CLL — the key resistance-market threat. CAR-T: lisocabtagene maraleucel (Breyanzi, BMS) received CLL approval in March 2024 for 3L+, carving a cellular-therapy pocket. PI3K inhibitors (idelalisib/Zydelig, duvelisib/Copiktra) are largely deprioritized on safety. Commercial lead takeaway: Calquence is the share-taker in 1L treatment-naive CLL vs Imbruvica, but pirtobrutinib, VenO fixed-duration, and Brukinsa erode the continuous-BTKi economic model.
AstraZeneca acquired 55% of Acerta Pharma for $4B, gaining acalabrutinib (Calquence), a next-gen BTK inhibitor for hematologic malignancies.
FDA granted accelerated approval to Calquence for mantle cell lymphoma, AstraZeneca's entry into the BTK inhibitor market vs AbbVie's Imbruvica.
Calquence exceeded $2B in annual revenue from CLL/SLL and MCL globally, establishing AstraZeneca as a major hematology player.
Calquence surpassed $2B+ annual sales, far exceeding the $4B acquisition cost. Established AstraZeneca's hematology franchise with strong commercial returns.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Acerta Pharma (this deal) | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
| AstraZeneca PLC / CinCor Pharma Inc. | 2023 | $1.8B | 78 |
← Browse all deals · How we score deals
More: 2015 deals · AstraZeneca PLC deals · Oncology deals